See more : Subros Limited (SUBROS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Bristol-Myers Squibb Company (BMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bristol-Myers Squibb Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Chord Energy Corporation (WLLBW) Income Statement Analysis – Financial Results
- Primech Holdings Ltd. Ordinary Shares (PMEC) Income Statement Analysis – Financial Results
- Go Metals Corp. (GOCO.CN) Income Statement Analysis – Financial Results
- Jiangxi Wannianqing Cement Co., Ltd. (000789.SZ) Income Statement Analysis – Financial Results
- Senheng New Retail Bhd (5305.KL) Income Statement Analysis – Financial Results
Bristol-Myers Squibb Company (BMY)
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.01B | 46.16B | 46.39B | 42.52B | 26.15B | 22.56B | 20.78B | 19.43B | 16.56B | 15.88B | 16.39B | 17.62B | 21.24B | 19.48B | 18.81B | 20.60B | 19.35B | 17.91B | 19.21B | 19.38B | 20.89B | 18.12B | 19.42B | 18.22B | 20.22B | 18.28B | 16.70B | 15.07B | 13.77B | 11.98B | 11.41B | 11.16B | 11.16B | 10.30B | 9.19B | 8.56B | 7.56B |
| Cost of Revenue | 10.69B | 10.14B | 9.94B | 11.77B | 8.08B | 6.55B | 6.07B | 4.95B | 3.91B | 3.93B | 4.62B | 4.61B | 5.60B | 5.28B | 5.14B | 6.40B | 6.22B | 5.96B | 5.93B | 5.99B | 7.59B | 6.39B | 5.58B | 4.01B | 4.86B | 4.23B | 3.87B | 3.45B | 3.19B | 2.79B | 2.72B | 2.56B | 2.68B | 2.63B | 2.46B | 2.30B | 2.14B |
| Gross Profit | 34.31B | 36.02B | 36.45B | 30.75B | 18.07B | 16.01B | 14.71B | 14.48B | 12.65B | 11.95B | 11.77B | 13.01B | 15.65B | 14.21B | 13.67B | 14.20B | 13.13B | 11.96B | 13.28B | 13.39B | 13.30B | 11.73B | 13.85B | 14.20B | 15.36B | 14.05B | 12.83B | 11.62B | 10.58B | 9.19B | 8.69B | 8.59B | 8.48B | 7.67B | 6.73B | 6.26B | 5.42B |
| Gross Profit Ratio | 76.24% | 78.04% | 78.57% | 72.31% | 69.10% | 70.98% | 70.80% | 74.54% | 76.39% | 75.24% | 71.81% | 73.84% | 73.65% | 72.92% | 72.67% | 68.95% | 67.86% | 66.75% | 69.14% | 69.10% | 63.66% | 64.74% | 71.30% | 77.97% | 75.96% | 76.86% | 76.81% | 77.13% | 76.84% | 76.69% | 76.16% | 77.03% | 75.95% | 74.47% | 73.23% | 73.14% | 71.67% |
| Research & Development | 9.30B | 9.51B | 10.20B | 11.14B | 6.15B | 6.35B | 6.41B | 4.94B | 5.92B | 4.53B | 3.73B | 3.90B | 3.84B | 3.57B | 3.65B | 3.59B | 3.28B | 3.07B | 2.75B | 2.50B | 2.28B | 2.22B | 2.26B | 1.94B | 1.84B | 1.58B | 1.39B | 1.28B | 1.20B | 1.11B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.28B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 162.00M | 91.00M | 160.00M | 877.00M | 165.00M | 158.00M | 4.20B | 3.56B | 4.08B | 4.83B | 4.86B | 4.92B | 5.11B | 5.02B | 4.66B | 3.92B | 3.90B | 3.86B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.40B | 7.81B | 7.69B | 7.66B | 4.87B | 4.55B | 4.69B | 4.91B | 4.84B | 4.82B | 4.94B | 5.02B | 957.00M | 977.00M | 1.14B | 1.55B | 1.47B | 1.35B | 1.48B | 1.41B | 1.42B | 1.30B | 1.43B | 1.67B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.77B | 7.81B | 7.69B | 7.66B | 4.87B | 4.55B | 4.85B | 5.00B | 5.00B | 5.70B | 5.10B | 5.18B | 5.16B | 4.54B | 5.21B | 6.38B | 6.32B | 6.27B | 6.58B | 6.43B | 6.08B | 5.22B | 5.34B | 5.53B | 6.99B | 6.73B | 6.41B | 5.87B | 5.32B | 4.53B | 5.98B | 6.34B | 5.46B | 5.04B | 5.45B | 4.30B | 3.79B |
| Other Expenses | 0.00 | 9.60B | 10.02B | 9.76B | 1.14B | 1.37B | 1.40B | 1.00B | 621.00M | 313.00M | 133.00M | 245.00M | 0.00 | 284.00M | -931.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 746.00M | 678.00M | 625.00M | 591.00M | 519.00M | 448.00M | 328.00M | 308.00M | 295.00M | 246.00M | 244.00M | 196.00M | 185.00M | 161.00M |
| Operating Expenses | 34.31B | 26.92B | 27.91B | 28.57B | 12.15B | 10.90B | 11.26B | 9.94B | 10.92B | 10.23B | 8.84B | 9.08B | 8.61B | 7.71B | 8.86B | 8.48B | 9.60B | 9.34B | 9.33B | 8.93B | 8.36B | 7.44B | 7.60B | 8.22B | 9.51B | 8.93B | 8.39B | 7.67B | 6.96B | 5.97B | 6.29B | 6.63B | 5.71B | 5.28B | 5.65B | 4.49B | 3.95B |
| Cost & Expenses | 27.76B | 37.06B | 37.85B | 40.34B | 20.23B | 17.44B | 17.33B | 14.89B | 14.83B | 14.17B | 13.45B | 13.69B | 14.21B | 12.98B | 14.00B | 14.88B | 15.82B | 15.29B | 15.26B | 14.92B | 15.95B | 13.82B | 13.17B | 12.23B | 14.37B | 13.16B | 12.26B | 11.11B | 10.15B | 8.76B | 9.01B | 9.20B | 8.39B | 7.91B | 8.11B | 6.79B | 6.09B |
| Interest Income | 0.00 | 171.00M | 120.00M | 121.00M | 464.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 91.00M | 75.00M | 54.00M | 130.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.17B | 1.23B | 1.33B | 1.42B | 656.00M | 183.00M | 196.00M | 167.00M | 184.00M | 203.00M | 199.00M | 182.00M | 145.00M | 145.00M | 184.00M | 310.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 410.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.81B | 10.29B | 10.76B | 10.49B | 1.81B | 703.00M | 872.00M | 626.00M | 376.00M | 467.00M | 763.00M | 681.00M | 801.00M | 744.00M | 707.00M | 816.00M | 892.00M | 927.00M | 929.00M | 909.00M | 789.00M | 735.00M | 781.00M | 746.00M | 678.00M | 625.00M | 591.00M | 519.00M | 448.00M | 328.00M | 308.00M | 295.00M | 246.00M | 244.00M | 196.00M | 185.00M | 161.00M |
| EBITDA | 19.37B | 19.23B | 20.19B | 5.04B | 7.44B | 6.85B | 6.20B | 4.63B | 2.94B | 3.41B | 4.40B | 3.51B | 7.93B | 7.09B | 6.61B | 6.60B | 4.42B | 3.31B | 4.67B | 5.37B | 5.72B | 4.84B | 5.89B | 6.73B | 5.92B | 5.08B | 5.03B | 4.47B | 4.06B | 3.55B | 2.71B | 2.26B | 3.01B | 2.63B | 1.28B | 1.96B | 1.63B |
| EBITDA Ratio | 43.03% | 43.16% | 43.51% | 34.85% | 25.24% | 26.91% | 27.52% | 28.91% | 14.70% | 13.44% | 19.71% | 24.74% | 33.54% | 33.75% | 22.92% | 28.99% | 24.59% | 21.12% | 23.16% | 28.31% | 28.37% | 35.29% | 52.78% | 40.01% | 32.61% | 35.73% | 29.78% | 29.40% | 38.63% | 35.64% | 21.78% | 19.53% | 25.41% | 23.70% | 11.12% | 20.60% | 18.72% |
| Operating Income | 17.24B | 10.33B | 10.16B | 5.13B | 5.46B | 5.12B | 3.45B | 4.54B | 1.73B | 1.71B | 2.93B | 3.93B | 6.65B | 5.61B | 5.74B | 4.24B | 3.53B | 2.62B | 3.95B | 4.46B | 4.95B | 4.30B | 6.25B | 5.99B | 5.85B | 5.12B | 4.44B | 3.95B | 3.62B | 3.22B | 2.40B | 1.96B | 2.77B | 2.39B | 1.08B | 1.77B | 1.47B |
| Operating Income Ratio | 38.31% | 22.37% | 21.90% | 12.06% | 20.90% | 22.69% | 16.61% | 23.36% | 10.45% | 10.79% | 17.89% | 22.31% | 31.29% | 28.77% | 30.51% | 20.59% | 18.23% | 14.63% | 20.57% | 23.03% | 23.68% | 23.70% | 32.19% | 32.86% | 28.94% | 28.01% | 26.57% | 26.24% | 26.26% | 26.88% | 21.05% | 17.57% | 24.79% | 23.19% | 11.79% | 20.68% | 19.41% |
| Total Other Income/Expenses | -8.80B | -10.64B | -9.30B | -7.42B | -938.00M | -426.00M | -108.00M | 1.45B | 347.00M | 667.00M | -40.00M | -1.59B | 344.00M | 121.00M | 163.00M | -247.00M | 6.00M | 610.00M | 353.00M | -46.00M | -612.00M | -1.60B | -2.94B | -508.00M | -81.00M | -818.00M | 44.00M | 60.00M | -1.21B | -666.00M | 168.00M | 27.00M | 121.00M | 135.00M | 194.00M | 119.00M | 161.00M |
| Income Before Tax | 8.44B | 7.71B | 8.10B | -6.87B | 4.98B | 6.01B | 5.13B | 5.92B | 2.17B | 2.38B | 2.89B | 2.34B | 6.98B | 6.07B | 5.60B | 5.47B | 3.53B | 2.64B | 4.52B | 4.42B | 4.69B | 2.65B | 2.90B | 5.48B | 5.77B | 4.27B | 4.48B | 4.01B | 2.40B | 2.56B | 2.57B | 1.99B | 2.89B | 2.52B | 1.28B | 1.89B | 1.63B |
| Income Before Tax Ratio | 18.75% | 16.71% | 17.46% | -16.16% | 19.03% | 26.64% | 24.70% | 30.45% | 13.09% | 14.99% | 17.64% | 13.28% | 32.86% | 31.16% | 29.79% | 26.56% | 18.27% | 14.71% | 23.51% | 22.80% | 22.47% | 14.61% | 14.91% | 30.07% | 28.52% | 23.34% | 26.84% | 26.64% | 17.45% | 21.32% | 22.53% | 17.81% | 25.87% | 24.50% | 13.90% | 22.07% | 21.54% |
| Income Tax Expense | 400.00M | 1.37B | 1.08B | 2.12B | 1.52B | 1.03B | 4.16B | 1.41B | 477.00M | 352.00M | 311.00M | -161.00M | 1.72B | 1.56B | 1.18B | 1.32B | 803.00M | 610.00M | 932.00M | 1.52B | 1.22B | 435.00M | 459.00M | 1.38B | 1.60B | 1.13B | 1.28B | 1.16B | 590.00M | 713.00M | 612.00M | 449.00M | 831.00M | 776.00M | 530.00M | 635.00M | 560.00M |
| Net Income | 8.03B | 6.33B | 6.99B | -9.00B | 3.44B | 4.95B | 1.01B | 4.46B | 1.62B | 2.00B | 2.56B | 1.96B | 3.71B | 3.10B | 10.61B | 5.25B | 2.17B | 1.59B | 3.00B | 2.39B | 3.11B | 2.07B | 5.25B | 4.71B | 4.17B | 3.14B | 3.21B | 2.85B | 1.81B | 1.84B | 1.96B | 1.96B | 2.06B | 1.75B | 747.00M | 1.25B | 1.07B |
| Net Income Ratio | 17.83% | 13.71% | 15.08% | -21.16% | 13.15% | 21.95% | 4.85% | 22.94% | 9.81% | 12.62% | 15.64% | 11.12% | 17.46% | 15.92% | 56.42% | 25.47% | 11.19% | 8.85% | 15.62% | 12.32% | 14.87% | 11.40% | 27.00% | 25.86% | 20.61% | 17.18% | 19.19% | 18.92% | 13.16% | 15.37% | 17.16% | 17.59% | 18.42% | 16.97% | 8.13% | 14.65% | 14.13% |
| EPS | 3.88 | 2.97 | 3.15 | -3.98 | 2.02 | 3.03 | 0.61 | 2.67 | 0.97 | 1.21 | 1.56 | 1.17 | 2.18 | 1.81 | 5.38 | 2.65 | 1.10 | 0.81 | 1.54 | 1.23 | 1.60 | 1.03 | 2.70 | 2.40 | 2.10 | 1.58 | 1.61 | 1.42 | 0.90 | 0.90 | 0.95 | 0.96 | 0.99 | 0.84 | 0.36 | 0.60 | 0.50 |
| EPS Diluted | 3.86 | 2.95 | 3.12 | -3.98 | 2.01 | 3.03 | 0.61 | 2.65 | 0.97 | 1.20 | 1.54 | 1.16 | 2.16 | 1.80 | 5.37 | 2.62 | 1.09 | 0.81 | 1.51 | 1.21 | 1.59 | 1.02 | 2.67 | 2.36 | 2.06 | 1.55 | 1.57 | 1.40 | 0.89 | 0.90 | 0.95 | 0.96 | 0.99 | 0.84 | 0.36 | 0.60 | 0.50 |
| Weighted Avg Shares Out | 2.07B | 2.13B | 2.22B | 2.26B | 1.71B | 1.63B | 1.65B | 1.67B | 1.67B | 1.66B | 1.64B | 1.67B | 1.70B | 1.71B | 1.97B | 1.98B | 1.97B | 1.96B | 1.95B | 1.94B | 1.94B | 2.00B | 1.94B | 1.97B | 1.98B | 1.99B | 1.99B | 2.01B | 2.02B | 2.04B | 2.06B | 2.04B | 2.08B | 2.08B | 2.08B | 2.09B | 2.14B |
| Weighted Avg Shares Out (Dil) | 2.08B | 2.15B | 2.25B | 2.26B | 1.71B | 1.64B | 1.65B | 1.68B | 1.68B | 1.67B | 1.66B | 1.69B | 1.72B | 1.73B | 1.98B | 2.00B | 1.98B | 1.96B | 1.98B | 1.98B | 1.95B | 2.02B | 1.97B | 2.00B | 2.03B | 2.03B | 2.04B | 2.04B | 2.03B | 2.04B | 2.06B | 2.04B | 2.08B | 2.08B | 2.08B | 2.09B | 2.14B |
U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #COBENFY--U.S. FDA Approves Bristol Myers Squibb's COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults.
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock rose late, signaling a breakout Friday.
US FDA approves Bristol Myers' schizophrenia drug
The U.S. health regulator approved Bristol Myers Squibb's schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental disorder without common side effects, the company said.
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
The Food and Drug Administration approved Bristol Myers Squibb's highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. The company expects the twice-daily pill, which will be sold...
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.
Bristol Myers Squibb Vs. AbbVie Stock
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – AbbVie stock . BMY stock trades at a much lower multiple of 2.2x revenues, versus 6.2x for ABBV.
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
2seventy bio, Inc TSVT and its partner Bristol Myers Squibb & Co BMY, will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone for newly diagnosed multiple myeloma (NDMM) who...
Raise Cash And Sell Trash
As a dividend growth investor focused on income, I recommend raising cash and selling lower-quality stocks due to potential recession risks. Historical data shows that rate cuts often precede recessions, making it prudent to increase cash positions and reduce exposure...
5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025
Healthcare is undervalued despite being the top sector for earnings growth, making it an attractive investment with solid fundamentals and the potential for explosive returns in 2025. Investing in healthcare ETFs or individual undervalued healthcare stocks can capitalize on the...
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #DAYBREAK--New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis.
Source: https://incomestatements.info
Category: Stock Reports